Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 170.88M | 8.76% |
| Gross profit | 79.13M | 1.57% |
| Net profit | 17.12M | 53.22% |
| EBITDA | 23.14M | 19.98% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €660.05M |
Number of shares | 35.35M |
52-week high/low | €22.53 - €16.65 |
Dividend yield | 2.35% |
Dividends TTM | €0.44 |
Beta | 0.36 |
P/E ratio | 12.67 |
PEG ratio | 0.24 |
P/B ratio | 0.83 |
P/S ratio | 0.95 |
Company profile
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
| Name | Mochida Pharmaceutical |
| CEO | Naoyuki Mochida |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| IPO | 01/01/2001 |
| Employees | 1,479 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Japan Exchange Group | 4534.T |
Frankfurt | MFY.F |
Düsseldorf | MFY.DU |